Filing Details

Accession Number:
0001479290-23-000007
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-10 20:06:54
Reporting Period:
2023-01-09
Accepted Time:
2023-01-10 20:06:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1678984 Tobin Schilke C/O Revance Therapeutics, Inc.
1222 Demonbreun Street, 20Th Floor
Nashville TN 37203
Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-09 1,701 $25.00 60,877 No 4 S Direct
Common Stock Disposition 2023-01-09 1,000 $28.00 59,877 No 4 S Direct
Common Stock Disposition 2023-01-09 1,000 $30.00 58,877 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.